Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Scilex Holding Company (SCLXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SCLXW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -51.77% | Avg. Invested days 17 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.14 | 52 Weeks Range 0.04 - 0.52 | Updated Date 06/14/2025 |
52 Weeks Range 0.04 - 0.52 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -146.93% | Operating Margin (TTM) -557.51% |
Management Effectiveness
Return on Assets (TTM) -69.26% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4990167 |
Shares Outstanding - | Shares Floating 4990167 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Scilex Holding Company
Company Overview
History and Background
Scilex Holding Company is a biotechnology company focused on acquiring, developing, and commercializing non-opioid therapies for the treatment of pain. It was originally founded as a subsidiary of Sorrento Therapeutics and later became a standalone public company. They aim to address unmet needs in the pain management market.
Core Business Areas
- Pain Management: Development and commercialization of non-opioid pain management products. Their focus is on providing alternative therapies for acute and chronic pain.
Leadership and Structure
The company's leadership team consists of experienced executives in the pharmaceutical and biotechnology industries. Their organizational structure is typical of a biotechnology company, with research and development, clinical trials, commercial operations, and administrative functions.
Top Products and Market Share
Key Offerings
- ZTlido: A lidocaine topical system for the treatment of post-herpetic neuralgia (PHN). Scilex has full commercial rights in the US. Competitors include generic lidocaine patches and other topical pain relievers. Market share data not readily available, revenue figures are crucial for assessing success. Competitors include Teva Pharmaceutical, Mylan (Viatris), and Endo International.
- SP-102 (SEMDEXA): A novel, non-opioid injectable corticosteroid formulation in Phase III clinical development for the treatment of sciatica pain. No revenue yet. Market potential depends on clinical trial outcomes and regulatory approval. Competitors include other injectable steroids and pain management therapies.
Market Dynamics
Industry Overview
The pain management market is a large and growing market, driven by an aging population, increasing prevalence of chronic diseases, and a growing demand for non-opioid pain relief options due to the opioid crisis.
Positioning
Scilex Holding Company is positioned as a company focused on non-opioid pain management therapies, aiming to provide alternatives to traditional opioid-based treatments. Their competitive advantage lies in their focus on innovative formulations and delivery systems.
Total Addressable Market (TAM)
The global pain management market is estimated to be worth hundreds of billions of dollars. Scilex is aiming to capture a significant portion of this market with their non-opioid therapies, particularly ZTlido and SEMDEXA.
Upturn SWOT Analysis
Strengths
- Focus on non-opioid pain management
- ZTlido commercialized and generating revenue
- SP-102 (SEMDEXA) in Phase III clinical trials
- Experienced management team
- Proprietary technology platform
Weaknesses
- Limited product portfolio
- Dependence on successful clinical trials for SP-102
- Relatively small company size
- Heavy reliance on debt financing.
- Ongoing litigation
Opportunities
- Expanding the market for ZTlido
- Successful commercialization of SP-102
- Acquiring additional pain management assets
- Partnerships and collaborations with other companies
- Addressing the opioid crisis
Threats
- Competition from larger pharmaceutical companies
- Generic competition for ZTlido
- Failure of SP-102 clinical trials
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- Endo International (ENDPQ)
- Teva Pharmaceutical Industries Ltd. (TEVA)
- Viatris (VTRS)
Competitive Landscape
Scilex is a smaller player competing with larger, established pharmaceutical companies. Their focus on non-opioid pain management is a potential advantage, but they need to successfully commercialize their products to gain market share.
Major Acquisitions
Vickers Medical
- Year: 2017
- Acquisition Price (USD millions): 0.2
- Strategic Rationale: Acquired to gain access to drug delivery systems.
Growth Trajectory and Initiatives
Historical Growth: Requires historical financial data and market performance metrics.
Future Projections: Future projections rely on analyst estimates, clinical trial outcomes, and market conditions.
Recent Initiatives: Focus on commercialization of ZTlido and the development of SP-102 are key initiatives.
Summary
Scilex Holding Company is a biotechnology firm focused on non-opioid pain relief, with ZTlido generating some revenue and SEMDEXA in late-stage development. Its smaller size and financial position represent key challenges. Successful clinical trials and commercialization will be vital to their growth trajectory. Competition from larger pharmaceutical firms represents a significant hurdle, along with litigation risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share estimates may vary and are subject to change. Financial data is based on available public information and may not be complete or accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scilex Holding Company
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2021-03-08 | President, CEO & Director Mr. Jaisim Shah | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 111 | Website https://www.scilexholding.com |
Full time employees 111 | Website https://www.scilexholding.com | ||
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.